Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Disruption of embryonic ROCK signaling reproduces the sarcomeric phenotype of hypertrophic cardiomyopathy
Kate E. Bailey, Guy A. MacGowan, Simon Tual-Chalot, Lauren Phillips, Timothy J. Mohun, Deborah J. Henderson, Helen M. Arthur, Simon D. Bamforth, Helen M. Phillips
Kate E. Bailey, Guy A. MacGowan, Simon Tual-Chalot, Lauren Phillips, Timothy J. Mohun, Deborah J. Henderson, Helen M. Arthur, Simon D. Bamforth, Helen M. Phillips
View: Text | PDF | Retraction
Research Article Cardiology

Disruption of embryonic ROCK signaling reproduces the sarcomeric phenotype of hypertrophic cardiomyopathy

  • Text
  • PDF
Abstract

Sarcomeric disarray is a hallmark of gene mutations in patients with hypertrophic cardiomyopathy (HCM). However, it is unknown when detrimental sarcomeric changes first occur and whether they originate in the developing embryonic heart. Furthermore, Rho kinase (ROCK) is a serine/threonine protein kinase that is critical for regulating the function of several sarcomeric proteins, and therefore, our aim was to determine whether disruption of ROCK signaling during the earliest stages of heart development would disrupt the integrity of sarcomeres, altering heart development and function. Using a mouse model in which the function of ROCK is specifically disrupted in embryonic cardiomyocytes, we demonstrate a progressive cardiomyopathy that first appeared as sarcomeric disarray during cardiogenesis. This led to abnormalities in the structure of the embryonic ventricular wall and compensatory cardiomyocyte hypertrophy during fetal development. This sarcomeric disruption and hypertrophy persisted throughout adult life, triggering left ventricular concentric hypertrophy with systolic dysfunction, and reactivation of fetal gene expression and cardiac fibrosis, all typical features of HCM. Taken together, our findings establish a mechanism for the developmental origin of the sarcomeric phenotype of HCM and suggest that variants in the ROCK genes or disruption of ROCK signaling could, in part, contribute to its pathogenesis.

Authors

Kate E. Bailey, Guy A. MacGowan, Simon Tual-Chalot, Lauren Phillips, Timothy J. Mohun, Deborah J. Henderson, Helen M. Arthur, Simon D. Bamforth, Helen M. Phillips

×

Figure 7

Downregulation of ROCK function leads to decreased phosphorylation of TnI and cTnT in vivo and in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Downregulation of ROCK function leads to decreased phosphorylation of Tn...
Pro-Q Diamond phosphoprotein stain was used to determine the total amount of the phosphorylated form of each protein (A), and Coomassie blue was used to determine total amount of each protein (B) at E13.5 in control, ROCKDNGata5-Cre, and ROCKDNTnT-Cre mutant hearts and in isolated primary mouse cardiomyocytes treated with and without the ROCK inhibitor Y27632. Representative gel images are shown for each type of sample analyzed. (C) Western blot analysis of the same blot shown in A and B, using specific antibodies, confirmed that the correct bands on the Pro-Q and Coomassie blue blots (arrows in A and B) were measured by densitometry for the proteins of interest: cTnT 40 kDa, cTnI 26 kDa, ssTnI 22 kDa, and Mlc2 18 kDa. (D–O) The relative amount of phosphorylated protein to total protein was calculated using densitometry for control and mutant heart or cell samples. A significant reduction in ph-cTnI and ph-ssTnI was observed in ROCKDNGata5-Cre (D and E) compared with controls. A significant reduction in ph-cTnI, ph-ssTnI, and additionally ph-TnT was observed in ROCKDNTnT-Cre mutants (H–J) compared with controls. Primary cardiomyocytes from E17.5 control embryos treated with Y27632 also showed a significant reduction in ph-cTnI (L), ph-ssTnI (M), and ph-TnT (N). No change in the levels of ph-Mlc2 was observed in any of the groups (G, K, and O). n = 4 for each genotype and n = 3 biological replicates for primary cardiomyocytes. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 by unpaired t test. CM, cardiomyocytes.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts